Skip to main content
DCTH logo

DCTH · Delcath Systems, Inc.

Track DCTH — free
$19.24 -0.46 (-2.34%) At close · Nov 19
Market Cap
$669.32M
Shares
34.79M
Volume · Nov 19 460.03K Avg daily vol (3M) 494.54K

Price & Indicators

 

Key stats

Close
$19.24
Open
$19.89
Day range
$18.99–19.89
52-week closing range
$8.19–21.77
Average volume, 30 days
633K
Short interest
1.8M · 5.1% of shares · 5.7 days
Short volume, last session
44%
Last earnings
Nov 9, 2026
Latest filing
10-Q · Nov 9
Price history
Jan 2020 to Nov 2026

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 9
Earnings call
Revenue guidance raised after record third quarter

Delcath reported third-quarter 2026 revenue of $35.1 million, net income of $7 million and adjusted EBITDA of $11.5 million, and raised full-year 2026 revenue guidance to $115 million to $117 million.

5 source passages
Delcath's record third quarter of $35.1 million in revenue, up 71% in the third quarter in 2025, reflects the growing adoption of HapsadoKit and the hard work of both the Delcath and Physician Treatment teams. For the third quarter of 2026, total revenue was $35.1 million compared with $20.6 million in the third quarter of 2025. Net income was $7 million, compared with $0.8 million in the third quarter of 2025. On a non-GAAP basis, adjusted EBITDA was $11.5 million, compared with $5.3 million in the prior year quarter. We are raising our full-year total revenue guidance to a range of $115 million to $117 million. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue reached $89,229 thousand and net income was $8,550 thousand

Delcath Systems reported nine-month revenue of $89,229 thousand versus $64,503 thousand and net income of $8,550 thousand versus $4,596 thousand, driven by continued U.S. commercial expansion and demand for HEPZATO.

Revenue $35.1M ▲ 70.7% Net income $6.95M ▲ 737.6% Diluted EPS $0.17 ▲ 750.0%
Read from the MD&A section
4 source passages
All references in this Quarterly Report on Form 10-Q to “we,” “our,” “us” and the “Company” refer to Delcath Systems, Inc., and its subsidiaries unless the context indicates otherwise. | Total revenues | 35,102 | 20,563 | 89,229 | 64,503 | | Net income | 6,952 | 830 | 8,550 | 4,596 | The increase in total revenue for the three and nine months ended September 30, 2026 compared to the same period in 2025 was due to the continued commercial expansion and demand of HEPZATO in the United States. Open the document at this passage
Nov 9
Current report 8-K
Revenue guidance increased to $115 million to $117 million

Delcath Systems, Inc. reported third-quarter 2026 revenue of $35.1 million, net income of $7.0 million, increased 2026 revenue guidance to $115 million to $117 million, and held $104.3 million in cash and investments with no debt.

Financial results
5 source passages
QUEENSBURY, NY – November 9, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2026. Total revenue for the quarter ending September 30, 2026 was $35.1 million compared to $20.6 million for the same period in the prior year. Net income was $7.0 million for the quarter ended September 30, 2026, compared to $0.8 million for the same period in the prior year. Total HEPZATO KIT and CHEMOSAT revenue to range from $115 million to $117 million, reflecting an increase in HEPZATO KIT volume of at least 41% over 2025 As of September 30, 2026, the Company had $104.3 million in cash and investments, and no debt. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$109.96M
Trailing 12 months
Net income (TTM)
$6.65M
Trailing 12 months
Revenue growth YoY
+70.7%
Year over year
Operating margin
5.2%
Trailing 12 months
P / E (TTM)
120.3
Trailing earnings · reciprocal yield 0.8%
FCF yield
3.0%
TTM · current market cap
Return on invested capital
5.5%
Trailing 12 months
Net cash
$55.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.4%
Year over year · more shares
Price change (1Y)
+126.1%
Trailing year
Short interest
5.1%
Latest settlement · 5.7 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 9, 2026
Q3 FY26

TL;DR. Revenue reached a record $35.1 million, margins and profitability improved, cash generation strengthened, the center network expanded, and full-year revenue guidance was raised. Breast-cancer enrollment remains slower than anticipated, fourth-quarter guidance includes a holiday-related step-down, R&D spending is expected to rise, SG&A expense increased, and new-center activation carries uncertainty.

Bullish
  • + Third-quarter revenue reached a record $35.1 million.
  • + Full-year 2026 revenue guidance was raised to $115 million to $117 million.
  • + Gross margin improved to 89% from 87%.
  • + Net income increased to $7 million and adjusted EBITDA increased to $11.5 million.
  • + The company generated $8.2 million from operations and ended with $104.3 million in cash and investments and no debt.
  • + The treatment-center network expanded, with at least 36 centers expected by year-end.
Bearish
  • − Breast-cancer trial enrollment has been slower than anticipated, and interim-analysis timing is not yet guided.
  • − R&D spending is expected to increase quarter over quarter into 2027.
  • − Fourth-quarter guidance includes a holiday-related step-down.
  • − Quarterly profitability may vary as investment continues.
  • − New-center activation carries uncertainty because scheduled procedures can be canceled.
  • − SG&A expense increased to $13.1 million from $10.3 million year over year.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +49%
above
Price vs 50-day avg +19%
above
RSI (14) 61
neutral
MACD trend Positive
52-week position 81%
mid-range
Momentum
relative strength
Very Strong
1-month return +30%
trailing
6-month return +82%
trailing
YTD return +91%
this year
Relative strength +87%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $16 › 200d $13 — 50d above 200d
Institutional flow Accumulating
+18% holders QoQ · +35 funds added
Insider flow Distributing
Net -$488.5K over 90 days · 100% sells
Short interest Falling
5.10% of shares out · ▼ -5.7% MoM · 5.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
145 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Excellent
Revenue growth +129%
Y/Y
Gross margin 86%
expanding
EPS growth +108%
Y/Y
Free cash flow $21.0M
Valuation P/E 120.3
rich
Buyback $16.0M
remaining
Balance sheet $32.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 62%
annualized · 1-yr
Max drawdown −22%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 9, 2026
full-year 2026
Total revenue Raised $115M – $117M
Aug 6, 2026 $104M – $108M changed to Nov 9, 2026 $115M – $117M
prior FY $85.23M midpoint +36.1% Y/Y
Gross margin 87% – 89%
fourth quarter of 2026
Total revenue $25.8M – $27.8M
prior qtr $35.1M midpoint −23.7% QoQ
Previous outlook earlier release · from the Earnings Call filed Aug 6, 2026

Still-open targets the latest release did not restate under the same label.

Gross margin · full year 86% – 89%
Guided vs delivered · last 1 settled
2025 annual guidance 2025
guided $83M – $85M
$85.23M Beat +1.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+49% Bullish
Price vs 50-day avg
+19% Bullish
RSI (14)
61 Neutral
MACD trend
Positive Bullish
52-week position
81% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $16 › 200d $13 — 50d above 200d
Institutional flow Accumulating
+18% holders QoQ · +35 funds added
Insider flow Distributing
Net -$488.5K over 90 days · 100% sells
Short interest Falling
5.10% of shares out · ▼ -5.7% MoM · 5.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
145 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8 Now $19 · 81% Range high $22
vs 200-day avg +49% vs 50-day avg +19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash and investments $104.3M as of September 30, 2026 —
Cash provided by operations $8.2M the quarter ended September 30, 2026 —
CHEMOSAT revenue $2.4M third quarter 2026 —
Gross margins 89% third quarter 2026 —
Active treatment centers 31 second quarter 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DCTH
Delcath Systems, Inc.
this stock
$669.32M +90.5% +129.1% 120.3 5.1%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
145
% held
59.6%
Net QoQ
+3.3M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
118
View
Short & Settlement
Short Interest Falling
Shares short
1.8M
Days to cover
5.7d
Change
-107.4K sh
View
Short Volume
Short vol %
44%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
232
Value
$3.3K
As of
Oct 20, 2026
View
Off-Exchange
Off-exchange %
30.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$488.5K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$85.2M
Net income (FY)
$2.7M
EPS diluted
$0.07
View
Buybacks
Authorized
$25.0M
Remaining
$16.0M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 9, 2026
This year
15

Delcath Systems reported nine-month revenue of $89,229 thousand versus $64,503 thousand and net income of $8,550 thousand versus $4,596 thousand, driven by continued U.S. commercial expansion and demand for HEPZATO.

View
Proposed Sales
Value
$7.3K
Shares
1.0K
Filed
Jul 9, 2024
View
Exempt Offerings
Offering
$7.0M
Filed
Mar 26, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Delcath Systems to Be Featured on…
Published
Nov 11, 2026
View

Performance

5D 20D 120D MTD YTD
DCTH -10.0% +30.4% +81.5% +37.0% +90.5%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -4.6% +36.7% +87.1% +42.3% +85.5%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$25.00M
Spent (derived)
$9.00M
Remaining
$16.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 872912 CUSIP 24661P807 13F (30d) 151 filings 132 filers Visit website Investor relations